GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)

Second quarter 2026 (Apr-Jun)

Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth of 34 percent in SEK.

Organic growth was 36 percent in local currencies. Excluding revenue from heart trials the organic growth was still 36 percent.

Thoracic sales increased by 53 percent in local currencies and by 52 percent excluding revenue from heart trials.